Patient-reported outcomes in the phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis

Authors
Category Primary study
ConferenceMultiple Sclerosis
Year 2016
This article has no abstract
Epistemonikos ID: 4eca70eeaad4e969132e235ebd449ba5f3c038df
First added on: Apr 29, 2026